Catch Me If You Can: Knowing How To Innovate Matters In China
Executive Summary
Given the host of recent and planned policy and regulatory changes in China, the traditional lines between multinational and local companies in the country will become increasingly blurred. These who know how to innovate in different ways in the fast-changing environment will have the most to gain, says the head of one major pharma industry trade group.
You may also be interested in...
China Leads Strong AstraZeneca Emerging Markets Charge In Q1
Despite a fall in overall revenue, emerging markets continued to perform strongly for AstraZeneca in the first quarter, becoming the UK group's single largest sales region globally, driven mainly by China.
Now What? Sanofi CEO Urges Incentives As China Embraces New Drugs
Delinking drug approvals from price agreements, and providing timely and adequate reimbursement coverage, are just some of the policy changes top big pharma executives would like to see if China is to create an operating environment conducive to innovation.
Spring Coming? EU Group Holds China To Fair Play Promises In Procurement
A major European business group in China is encouraged by recent signals of further policy reforms, but says in a new report it would like to see further progress on drug and device tenders, the lifting of indirect competition restrictions, and full implementation of the central push for a level playing field for foreign firms.